Winning the audience vote was a strong signal that the problem resonates beyond the medical community.
– Keano Venner
HEMˣ was presented at Schongauer Startup Day to founders, investors, local stakeholders, and the broader public.
The pitch focused on a clear problem:
Venous access is common — but difficult access still causes pain, delays, and unnecessary stress.
For HEMˣ, the event was an opportunity to show how automation, imaging, and precision guidance could support a more reliable approach to vascular access.
A problem people immediately understand
Some healthcare challenges are highly technical.
Others are immediately relatable.
Difficult blood draws belong to the second category. Many people have experienced them themselves or know someone who has. A missed vein, a repeated puncture attempt, a stressful moment before treatment — these are not abstract problems.
They are familiar.
That made the value of HEMˣ tangible during the pitch. The audience could understand not only the technical ambition behind the project, but also the human relevance of the problem.
From clinical relevance to public validation
The presentation showed how HEMˣ aims to make vascular access more reliable through automated vein detection, intelligent evaluation, and controlled puncture guidance.
The response confirmed that HEMˣ addresses a challenge people immediately recognize.
Winning the audience vote was more than a positive moment at the event. For an early-stage MedTech project, it was a valuable form of public validation.
It showed that the need is:
- Recognizable
- Relatable
- Emotionally relevant
- Commercially meaningful
That matters.
Because for MedTech innovation to move forward, the problem must be understood not only by experts, but also by the people affected by it.
Feedback, visibility, and momentum
Schongauer Startup Day also provided important feedback on use cases, market potential, and communication.
The conversations around the pitch helped sharpen how HEMˣ explains its mission: not as technology for technology’s sake, but as a focused solution for one of the most frequent and underestimated procedures in healthcare.
The event also increased HEMˣ’s visibility within the regional startup ecosystem and created new connections with supporters, founders, investors, and stakeholders.
For a young MedTech initiative, this kind of exposure is valuable.
It creates momentum.
Turning recognition into progress
The audience vote strengthened confidence in the direction of the company.
It reinforced the idea that HEMˣ is addressing a real and widely understood challenge — one that connects clinical relevance with patient experience and workflow efficiency.
But recognition is only meaningful if it leads to progress.
The next focus is to turn this momentum into:
- Development partnerships
- Pilot opportunities
- Continued technical progress
- Stronger medical and industry feedback
For HEMˣ, Schongauer Startup Day was not the finish line.
It was another step toward building a more reliable standard for vascular access.
